Common use of Use of Trademarks and House Marks Clause in Contracts

Use of Trademarks and House Marks. The Joint Steering Committee will determine which Trademark or Trademarks will be used in marketing Products and Additional Products in the Territory. Further, all packaging, and package inserts for the Products in the Collaboration Territory shall, along with the GSK brand name and logo or other identifying markings of GSK or its Affiliates (collectively, the “GSK House Marks”), include the VALEANT brand name and logo (such VALEANT brand name and logo, collectively “VALEANT House Marks”) in reasonable size and prominence as allowed by applicable Law; it being understood that the exact size, placement and prominence of such VALEANT House Marks shall be determined by GSK in its reasonable discretion. VALEANT hereby grants to GSK a non-exclusive, royalty-free license, with the right to grant sublicenses as provided in Section 1.3, to use the VALEANT House Marks in connection with the developing making, having made, use, sale, offering for sale, importation, packaging, distributing and promotion of the Product in the Field in the Collaboration Territory. Solely to the extent necessary to preserve VALEANT’s legal rights in the XXXXXXX Xxxxx Xxxxx, XXX shall submit to VALEANT, not less than fifteen (15) days prior to their proposed distribution, representative packaging for the Product displaying the VALEANT House Marks to VALEANT for VALEANT’s review and written approval solely with respect to GSK’s use of the VALEANT House Marks, which approval will not be unreasonably withheld or delayed. If VALEANT has not responded within thirty (30) days after the submission of such packaging for the Product, VALEANT’s approval to GSK’s use of the VALEANT House Marks on such packaging and will be deemed to have been received. GSK may make any subsequent changes to packaging bearing the VALEANT House Marks, other than changes to the VALEANT House Marks without the subsequent approval from VALEANT. For clarity, only GSK House Marks will be used on Products in the GSK Territory and Additional Products in the Territory.

Use of Trademarks and House Marks. The Joint Steering Committee will determine which Trademark or Trademarks will be used in marketing Products and Additional Products Product in the Territory. Further, all packaging, and package inserts for the Products Product in the Collaboration Territory shall, along with the GSK brand name and logo or other identifying markings of GSK or its Affiliates (collectively, the “GSK House Marks”), include the VALEANT Amicus brand name and logo (such VALEANT Amicus brand name and logo, collectively “VALEANT Amicus House Marks”) in reasonable size and prominence as allowed by applicable Law; it being understood that the exact size, placement and prominence of such VALEANT Amicus House Marks shall be determined by GSK in its reasonable discretion. VALEANT Amicus hereby grants to GSK a non-exclusive, royalty-free license, with the right to grant sublicenses as provided in Section 1.32.2, to use the VALEANT Amicus House Marks in connection with the developing developing, making, having made, use, sale, offering for sale, importation, packaging, distributing and promotion of the Product Products in the Field in the Collaboration Territory. The ownership and all goodwill from the use of the Amicus House Marks shall vest in and inure to the benefit of Amicus. Solely to the extent necessary to preserve VALEANTAmicus’s legal rights in the XXXXXXX Xxxxxx Xxxxx Xxxxx, XXX shall submit to VALEANTAmicus, not less than fifteen (15) days prior to their proposed distribution, representative packaging for the Product displaying the VALEANT Amicus House Marks to VALEANT for VALEANTAmicus’s review and written approval solely with respect to GSK’s use of the VALEANT Amicus House Marks, which approval will not be unreasonably withheld or delayed. If VALEANT Amicus has not responded within thirty (30) days after the submission of such packaging for the Product, VALEANTAmicus’s approval to GSK’s use of the VALEANT Amicus House Marks on such packaging and will be deemed to have been received. GSK may make any subsequent changes to packaging bearing the VALEANT Amicus House Marks, other than changes to the VALEANT Amicus House Marks Marks, without the subsequent approval from VALEANT. For clarity, only GSK House Marks will be used on Products in the GSK Territory and Additional Products in the TerritoryAmicus.

Use of Trademarks and House Marks. The Joint Steering Committee will determine which Trademark or Trademarks will be used in marketing Products and Additional Products Product in the Territory. Further, all packaging, and package inserts for the Products Product in the Collaboration Territory shall, along with the GSK brand name and logo or other identifying markings of GSK or its Affiliates (collectively, the “GSK House Marks”), include the VALEANT Amicus brand name and logo (such VALEANT Amicus brand name and logo, collectively “VALEANT Amicus House Marks”) in reasonable size and prominence as allowed by applicable Law; it being understood that the exact size, placement and prominence of such VALEANT Amicus House Marks shall be determined by GSK in its reasonable discretion. VALEANT Amicus hereby grants to GSK a non-exclusive, royalty-free license, with the right to grant sublicenses as provided in Section 1.32.2, to use the VALEANT Amicus House Marks in connection with the developing developing, making, having made, use, sale, offering for sale, importation, packaging, distributing and promotion of the Product Products in the Field in the Collaboration Territory. The ownership and all goodwill from the use of the Amicus House Marks shall vest in and inure to the benefit of Amicus. Solely to the extent necessary to preserve VALEANTXxxxxx’s legal rights in the XXXXXXX Xxxxx XxxxxAmicus House Marks, XXX GSK shall submit to VALEANTAmicus, not less than fifteen (15) days prior to their proposed distribution, representative packaging for the Product displaying the VALEANT Amicus House Marks to VALEANT for VALEANTXxxxxx’s review and written approval solely with respect to GSK’s use of the VALEANT Amicus House Marks, which approval will not be unreasonably withheld or delayed. If VALEANT Xxxxxx has not responded within thirty (30) days after the submission of such packaging for the Product, VALEANTXxxxxx’s approval to GSK’s use of the VALEANT Amicus House Marks on such packaging and will be deemed to have been received. GSK may make any subsequent changes to packaging bearing the VALEANT Amicus House Marks, other than changes to the VALEANT Amicus House Marks Marks, without the subsequent approval from VALEANT. For clarity, only GSK House Marks will be used on Products in the GSK Territory and Additional Products in the TerritoryAmicus.

Use of Trademarks and House Marks. 6.3.1 The Joint Commercialization Subcommittee will determine, and the Joint Steering Committee will determine confirm, which GSK Trademark or GSK Trademarks will be used in marketing Products in the GSK Territory and Additional Products the Amicus Territory, with the goal of identifying a global GSK Trademark for each Product that may be used in the Amicus Territory and throughout the GSK Territory. In the event that a GSK Trademark selected by the Joint Commercialization Subcommittee and Joint Steering Committee is not registerable in the Amicus Territory or throughout the GSK Territory, or is not approved by the applicable Regulatory Authorities for a Product in a country in the Territory, the Joint Commercialization Subcommittee shall have the right to select (subject to approval by the Joint Steering Committee) an alternative GSK Trademark for use in connection with such Product in such country, it being understood that the Parties shall mutually agree upon the pool of alternative GSK Trademarks for such purposes. Further, all packaging, Neither Party shall have the right to select and use a Trademark or a GSK Trademark in connection with a Product without the prior written consent and approval of the Joint Commercialization Subcommittee and the Joint Steering Committee. All packaging and package inserts for the Products Product in the Collaboration GSK Territory shall, along with will include the GSK brand name and logo or other identifying markings of GSK or its Affiliates (collectively, the “GSK House Marks”), and all packaging and package inserts for Product in the Amicus Territory will include the VALEANT brand name and logo (such VALEANT Amicus brand name and logo, or other identifying markings of ****** - Material has been omitted and filed separately with the Commission. Amicus (collectively “VALEANT Amicus House Marks”) in reasonable size and prominence as allowed by applicable Law; it being understood that the exact size, placement and prominence of such VALEANT House Marks shall be determined by GSK in its reasonable discretion. VALEANT hereby grants to GSK a non-exclusive, royalty-free license, with the right to grant sublicenses as provided in Section 1.3, to use the VALEANT House Marks in connection with the developing making, having made, use, sale, offering for sale, importation, packaging, distributing and promotion of the Product in the Field in the Collaboration Territory. Solely to the extent necessary to preserve VALEANT’s legal rights in the XXXXXXX Xxxxx Xxxxx, XXX shall submit to VALEANT, not less than fifteen (15) days prior to their proposed distribution, representative packaging for the Product displaying the VALEANT House Marks to VALEANT for VALEANT’s review and written approval solely with respect to GSK’s use of the VALEANT House Marks, which approval will not be unreasonably withheld or delayed. If VALEANT has not responded within thirty (30) days after the submission of such packaging for the Product, VALEANT’s approval to GSK’s use of the VALEANT House Marks on such packaging and will be deemed to have been received. GSK may make any subsequent changes to packaging bearing the VALEANT House Marks, other than changes to the VALEANT House Marks without the subsequent approval from VALEANT. For clarity, only GSK House Marks will be used on Products in the GSK Territory and Additional Products in the Territory.